Search Results for: angioimmunoblastic T-cell lymphoma

March 5, 2020March 5, 2020

Tipifarnib Granted FDA Fast Track Designation for T-cell Lymphomas

News

Kura Oncology‘s investigational lead therapy candidate tipifarnib was given fast track status by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with different subtypes of ... Read more

February 27, 2020February 27, 2020

Corvus’ CPI-818 Shows Promising Early Results in T-cell Lymphomas, Data Finds

News

Twice-daily treatment with Corvus Pharmaceuticals‘ potential therapy for T-cell lymphomas, CPI-818, is showing promising safety and tolerability, and preliminary signs of efficacy, according to Phase 1/1b results. The early clinical ... Read more

December 12, 2019December 12, 2019

Health Canada Approves Adcetris-Chemo Combo for Initial Peripheral T-cell Lymphoma Treatment

News

Health Canada has expanded its approval of Adcetris (brentuximab vedotin) in combination with a chemotherapy regimen for the first-line treatment of peripheral T-cell lymphomas expressing the CD30 marker. The approval is ... Read more

August 9, 2019September 9, 2019

Cerdulatinib Alone or with Rituxan Effective in Previously Treated Follicular Lymphoma, Data Show

News

Treatment with the oral therapy cerdulatinib alone or in combination with Rituxan (rituximab) shows durable efficacy, including some complete responses, in patients with follicular lymphoma who failed prior medications, according ... Read more

May 14, 2019

Health Canada Approves Adcetris-Chemo for Advanced Classical Hodgkin’s Lymphoma

News

Health Canada has approved Seattle Genetics‘ submission requesting approval of Adcetris (brentuximab vedotin) in combination with standard chemotherapy as a frontline treatment for patients with advanced (stage IV) classical Hodgkin’s lymphoma. ... Read more

June 11, 2018

First-line GEM-P Chemo Fails to Improve Response Rates in Peripheral T-cell Lymphomas, Results Show

News

The GEM-P chemotherapy regimen composed of gemcitabine, Platinol (cisplatin), and the corticosteroid methylprednisolone failed to improve response rates of peripheral T-cell lymphoma patients who have not received prior treatment, according to Phase 2 trial results. ... Read more

June 16, 2016August 23, 2016

Phase 2 Study of Plitidepsin, a Potential Treatment for Rare T-cell Lymphoma, Begins

News

PharmaMar announced the start of a multicenter and prospective Phase 2 clinical trial to evaluate the efficacy of plitidepsin, a potential treatment option for adult patients with relapsed and refractory angioimmunoblastic T-cell lymphoma (AITL). Plitidepsin ... Read more

February 5, 2016May 13, 2016

Potential Lymphoma Drug, Aplidin, May Become Available in 12 Asian Countries

News

PharmaMar has signed an agreement with Singapore-based Specialised Therapeutics Asia to market Aplidin (plitidepsin), a marine-based anti-tumor compound under development for the treatment of hematological tumors, including lymphoma, in 12 Southeast Asian ... Read more